Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
Author:
Funder
Agenzia Italiana del Farmaco
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/29/12/2328/27342124/mdy414.pdf
Reference20 articles.
1. Trastuzumab containing regimens for early breast cancer;Moja;Cochrane Database Syst Rev,2012
2. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer;Piccart-Gebhart;N Engl J Med,2005
3. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer;Romond;N Engl J Med,2005
4. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011
5. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer;Joensuu;N Engl J Med,2006
Cited by 126 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Reply to M. Kusumoto et al;Journal of Clinical Oncology;2024-09-01
2. Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer;JAMA Network Open;2024-08-26
3. Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023;ESMO Open;2024-07
4. Unpacking Trastuzumab-Induced Cardiomyopathy: A Cardiac Conundrum;Hearts;2024-06-20
5. Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories;Frontiers in Pharmacology;2024-06-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3